Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
about
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingBrain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.D1 dopamine receptor-mediated LTP at GABA synapses encodes motivation to self-administer cocaine in rats.Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.Astrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology?Differential subcellular distribution of rat brain dopamine receptors and subtype-specific redistribution induced by cocaine.Pathophysiology of parkinsonism.Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.Nigral dopamine loss induces a global upregulation of presynaptic dopamine D1 receptor facilitation of the striatonigral GABAergic outputL-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.Nicotine and Parkinson's disease: implications for therapy.G protein-coupled receptor kinases: more than just kinases and not only for GPCRsModulating neuromodulation by receptor membrane traffic in the endocytic pathway.Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapsesStriatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian ratsPalmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson ModelStriatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease.Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.Mavoglurant as a treatment for Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.G protein-coupled receptor kinases as regulators of dopamine receptor functions.Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders.Current Concepts on the Physiopathological Relevance of Dopaminergic ReceptorsNeurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulationRole of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease.Understanding and prevention of "therapy-" induced dyskinesias.Mathematical insights into the effects of levodopa.Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease.Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease.
P2860
Q27021464-E42205CE-0E97-42C3-BBAC-B80B2960F41EQ28582674-4D21CF9D-88F3-4C10-9C0E-97589C87DAA6Q30833645-7B57D5BC-F655-4E06-B804-B443F3B13458Q33319566-ED7EDCB6-FFFD-44B5-B4C6-F7169272B402Q33573158-E0719241-B863-4079-9D65-7B93461C2F9CQ34044620-9EE371BA-52B9-4F27-8AC4-403A072DADC2Q34094008-62A69806-B536-4784-9706-4CD3141DDBB4Q34105586-1A6C7D73-21EF-4C59-BAB4-1CC7EF9E6A2BQ34238909-0E23D7FA-CFB8-476B-B268-056F86113999Q34662380-22B40133-2D0D-476E-9D6D-02383135D736Q34777496-87EE40F1-1E68-4287-9A77-D8B13EAE56E4Q35000569-330D119A-F08E-42A1-AA47-AC9E42579A92Q35178497-170EE158-A7DA-4F7A-8C51-734FF58323DCQ35424424-783A48A9-AB37-46F4-9573-FB1D88858AD6Q35601652-5441EC43-EE85-4309-91B2-9DDAF3147CB5Q35621624-64CDCDAA-2AE0-4616-AF5C-4487A9FEE00FQ36392981-671F52B2-D110-4819-B0A6-D9BFB272A162Q36883134-13EFCDEE-573C-421E-8ABF-75F5F7331EC8Q37048087-A8861482-5299-4E98-92D9-DE34CEC40C1BQ37103028-D6986C5C-7A23-4A2A-A398-854C3B867827Q37162053-B0D5ACEA-E1F6-424B-B1E4-7F77AC9EC8BAQ37208065-B6CC8A7F-D37B-4606-A060-D72E2971063FQ37925513-EE471B17-164D-4356-BC9B-B9928122EB31Q37973462-6308EDCC-E759-45F7-A08C-027C99B9EC8EQ38099828-AEBA2900-FF33-4434-82AC-49ADE9C204FEQ38207680-C076A294-E409-4604-AD06-91E4478A1661Q38222814-68AC14CA-ECE1-426F-9DFD-13674D4B6B1DQ38262418-78CEEC7C-D8AE-4BE7-8023-20020CB6D75DQ38834292-B4E3278C-E94A-48D8-AA85-0891A184AE65Q38931640-49D4BB09-A213-4B40-8D61-F195D954766DQ39067400-A0DC76EB-7BC2-4B40-BB3B-B0134E814B04Q39147170-7E18870C-9597-436E-8C2B-5FB93674A071Q39405720-BCA43E85-AD00-47E7-8760-B95541919D16Q41853023-0140516A-B2FE-441A-8D99-43D4870356C2Q42052125-05D12DFB-D45A-4638-AD94-B4E1514A827BQ42224924-CFA1C9CE-4C86-441C-A341-73D87782C003Q42512289-1D79686B-5956-4916-9DB6-9CEA4ADBE2EFQ45007058-FE1A46DE-069D-4475-A0E9-27A88483AB1BQ46794787-CB99FB0B-96A7-4888-B0DB-0A8CEB0802B1Q47301971-394CBC2F-2FF3-4F67-B0FA-C8547F2B3BDF
P2860
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Altered D
@nl
Altered D(1) dopamine receptor ...... dyskinetic non-human primates.
@en
type
label
Altered D
@nl
Altered D(1) dopamine receptor ...... dyskinetic non-human primates.
@en
prefLabel
Altered D
@nl
Altered D(1) dopamine receptor ...... dyskinetic non-human primates.
@en
P2093
P1476
Altered D(1) dopamine receptor ...... dyskinetic non-human primates
@en
P2093
Bertrand Bloch
Céline Guigoni
P304
P356
10.1016/J.NBD.2007.02.001
P577
2007-02-09T00:00:00Z